Kalkine has a fully transformed New Avatar.

Switch to Old version
1800-272-662
Shopping Cart 0
countryflagAU
Login

NeoGenomics Inc

Healthcare US NEO

8.56USD
-0.36(4.04%)

Last update at 2026-03-10T20:26:00Z

Day Range

8.509.12
LowHigh

52 Week Range

11.0321.22
LowHigh

Fundamentals

  • Previous Close 8.92
  • Market Cap1804.57M
  • Volume1447965
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-20.50900M
  • Revenue TTM610.66M
  • Revenue Per Share TTM4.86
  • Gross Profit TTM 187.90M
  • Diluted EPS TTM-0.66

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -159.34200M -15.07500M -14.05600M 3.65M 3.82M
Minority interest - - - - -
Net income -144.25000M -8.34700M 4.17M 8.01M 2.64M
Selling general administrative 243.36M 221.35M 143.79M 127.99M 84.82M
Selling and marketing expenses 67.32M 62.59M 47.86M 47.35M 29.40M
Gross profit 187.90M 187.06M 185.89M 196.84M 127.27M
Reconciled depreciation 69.43M 53.35M 35.72M 30.27M 21.73M
Ebit -153.10700M -9.99300M -2.13100M 8.38M 10.05M
Ebitda -83.89000M 43.36M 33.59M 38.65M 31.79M
Depreciation and amortization 69.22M 53.35M 35.72M 30.27M 21.73M
Non operating income net other -0.21300M -0.49900M 10.46M -5.64800M 0.01M
Operating income -153.10700M -9.99300M -2.13100M 8.38M 10.04M
Other operating expenses 662.84M 603.08M 458.44M 395.82M 266.70M
Interest expense 1.51M 5.08M 7.02M 3.71M 6.23M
Tax provision -15.09200M -6.72800M -18.22800M -4.36100M 1.18M
Interest income - - - 3.71M 6.23M
Net interest income -1.50600M -5.08200M -7.01900M -3.71300M -6.23000M
Extraordinary items - - - - -
Non recurring 4.52M - - - -
Other items - - - - -
Income tax expense -15.09200M -6.72800M -18.22800M -4.36100M 1.18M
Total revenue 509.73M 484.33M 444.45M 408.83M 276.74M
Total operating expenses 341.00M 305.81M 199.88M 183.83M 117.22M
Cost of revenue 321.83M 297.27M 258.56M 211.99M 149.48M
Total other income expense net -6.23500M -5.08200M -11.92500M -4.73100M 0.01M
Discontinued operations - - - - -
Net income from continuing ops -144.25000M -8.34700M 4.17M 8.01M 2.64M
Net income applicable to common shares -144.25000M -8.34700M 4.17M 8.01M 6.09M
Preferred stock and other adjustments - - - - 10.20M
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 1681.23M 1740.03M 1869.78M 988.33M 709.51M
Intangible assets 373.13M 408.26M 442.32M 120.65M 126.64M
Earning assets - - - - -
Other current assets 8.24M 8.08M 8.19M 4.55M 9.07M
Total liab 739.69M 742.01M 761.50M 294.04M 202.10M
Total stockholder equity 941.54M 998.02M 1108.28M 694.29M 507.41M
Deferred long term liab - 34.75M 55.48M 5.42M 15.57M
Other current liab 68.23M -7.55700M 56.10M -4.02900M -1.61000M
Common stock 0.13M 0.13M 0.12M 0.11M 0.10M
Capital stock 0.13M 0.13M 0.12M 0.11M 0.10M
Retained earnings -247.05500M -159.08700M -14.83700M -7.18500M -11.35700M
Other liab - 47.80M 69.50M 10.44M 17.13M
Good will 522.77M 522.77M 527.12M 211.08M 198.60M
Other assets - 5.11M 7.17M 54.45M 2.85M
Cash 342.49M 263.18M 316.83M 228.71M 173.02M
Cash and equivalents - - - - -
Total current liabilities 96.30M 89.93M 87.23M 73.18M 63.90M
Current deferred revenue 2.13M 7.56M 5.19M 4.03M 1.61M
Net debt 269.19M 347.75M 295.96M -10.48900M -40.14100M
Short term debt 5.61M 6.65M 8.02M 7.81M 13.81M
Short long term debt - - - - 5.00M
Short long term debt total 611.68M 610.93M 612.79M 218.22M 132.88M
Other stockholder equity 1190.14M 1160.88M 1123.63M 701.36M 520.28M
Property plant equipment - 102.50M 211.66M 85.87M 64.19M
Total current assets 596.81M 605.29M 681.51M 448.73M 290.74M
Long term investments - - 0.00000M 29.55M -
Net tangible assets - 67.00M 138.84M 362.56M 182.17M
Short term investments 72.72M 174.81M 198.56M 67.55M -
Net receivables 131.23M 119.71M 112.13M 106.84M 94.24M
Long term debt 538.20M 535.32M 532.48M 168.12M 91.83M
Inventory 24.16M 24.28M 23.39M 29.53M 14.40M
Accounts payable 20.33M 83.28M 17.92M 65.38M 50.09M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income -1.67400M -3.89900M -0.63800M 0.01000M -1.61800M
Additional paid in capital - - - - -
Common stock total equity - 0.13M 0.12M 0.11M 0.10M
Preferred stock total equity - - - - -
Retained earnings total equity - -159.08700M -14.83700M -7.18500M -11.35700M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.74M -29.64100M 7.17M 21.01M 2.85M
Deferred long term asset charges - - - - -
Non current assets total 1084.42M 1134.74M 1188.27M 539.60M 418.77M
Capital lease obligations 73.48M 75.61M 80.31M 50.10M 24.03M
Long term debt total - 535.32M 532.48M 168.12M 115.86M
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 0.52M -133.82100M -93.34500M -19.63000M -139.68700M
Change to liabilities -13.30300M 5.15M -3.97000M -9.00100M 12.92M
Total cashflows from investing activities 0.52M -632.36700M -159.44100M -19.63000M -139.68700M
Net borrowings -0.75800M 331.36M 96.93M -5.30900M -2.03900M
Total cash from financing activities 11.83M 725.28M 235.60M 159.47M 91.96M
Change to operating activities -9.71700M -4.60000M -61.74700M -0.36700M -1.83400M
Net income -144.25000M -8.34700M 4.17M 8.01M 2.64M
Change in cash -53.64700M 66.19M 77.62M 163.21M -3.01000M
Begin period cash flow 316.83M 250.63M 173.02M 9.81M 12.82M
End period cash flow 263.18M 316.83M 250.63M 173.02M 9.81M
Total cash from operating activities -65.99300M -26.72300M 1.46M 23.37M 44.79M
Issuance of capital stock 12.59M 423.21M 147.60M 171.98M 144.09M
Depreciation 69.43M 53.35M 35.72M 30.27M 21.73M
Other cashflows from investing activities 12.10M -15.00000M -37.00000M 0.40M -125.37700M
Dividends paid - - - - 9.60M
Change to inventory -1.10000M 1.63M -15.19700M -5.75400M 0.73M
Change to account receivables -7.58100M -4.69100M -12.60100M -17.30100M 0.21M
Sale purchase of stock 12.59M 15.08M 20.31M 11.20M -50.09600M
Other cashflows from financing activities 0.52M 305.12M 191.15M 98.94M 18.62M
Change to netincome 27.91M -69.86900M 13.07M 11.02M 6.96M
Capital expenditures 30.89M 64.14M 29.10M 20.03M 14.31M
Change receivables -7.58100M -4.69100M -12.60100M -17.30100M 0.21M
Cash flows other operating 0.06M 7.69M -24.26000M 5.74M -0.94800M
Exchange rate changes - - - - -0.06800M
Cash and cash equivalents changes -53.64700M 66.19M 77.62M 163.21M -3.01000M
Change in working capital -31.70100M -4.60000M -61.74700M -32.42300M 12.51M
Stock based compensation 24.67M 22.46M 10.21M 10.00M 6.96M
Other non cash items 31.95M 13.61M 12.15M 6.03M 0.54M
Free cash flow -96.88400M -90.86500M -27.63600M 3.34M 30.48M

Peer Comparison

Sector: Healthcare Industry: Diagnostics & Research

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NEO
NeoGenomics Inc		 -0.36 4.04% 8.56 - 222.22 3.04 1.91 3.37 -113.3234
TMO
Thermo Fisher Scientific Inc		 -9.89 1.94% 500.08 34.71 23.87 4.62 4.43 5.29 20.89
DHR
Danaher Corporation		 -3.58 1.80% 195.22 29.09 28.01 5.67 3.20 6.00 19.09
A
Agilent Technologies Inc		 -1.21 1.04% 115.43 34.36 26.39 6.59 7.14 6.78 23.56
IDXX
IDEXX Laboratories Inc		 -11.6 1.90% 598.85 49.99 45.66 11.29 27.85 11.46 34.46

Reports Covered

Stock Research & News

View All

Profile

NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. It also provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. In addition, the company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization. NeoGenomics, Inc. was founded in 2001 and is headquartered in Fort Myers, Florida.

NeoGenomics Inc

9490 NeoGenomics Way, Fort Myers, FL, United States, 33912

Key Executives

Name Title Year Born
Mr. George A. Cardoza Pres & COO of Lab Operations 1962
Ms. Kathryn B. McKenzie Interim Chief Culture Officer, Chief Sustainability & Risk Officer 1984
Mr. Christopher Michael Smith BSc CEO & Director 1963
Mr. Jeffrey S. Sherman M.B.A. Chief Financial Officer 1966
Ms. Cynthia J. Dieter Chief Accounting Officer 1975
Mr. John Mooney Chief Technology Officer NA
Dr. Shashikant Kulkarni Facmg, M.B.A., M.S., Ph.D. Pres of Lab Operations & Chief Scientific Officer NA
Charlie Eidson Director of Investor Relations and Corp. Devel. NA
Mr. Hutan Hashemi J.D. Chief Compliance Officer NA
Ms. Ali Olivio Gen. Counsel & Corp. Sec. NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.